Latest From Zydus Cadila
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.
Roche’s subcutaneous (SC) Herceptin (trastuzumab) has been declined a trial waiver in India, at least for now, stretching potential launch timelines for the product significantly. The company emphasizes that a harmonized regulatory approach could best serve patient interests for therapies like Herceptin that come with a ‘long history of proven efficacy’.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Zydus Cadila
- Senior Management
- Pankaj R Patel, Chmn. & Managing Dir.
- Contact Info
Phone: (91) 79 26868100
Zydus Tower, Satellite Cross Roads
Ahmedabad , 380015
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.